AGN — Algernon Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- CA$2.44m
- CA$2.08m
- 10
- 39
- 59
- 28
Annual income statement for Algernon Pharmaceuticals, fiscal year end - August 31st, CAD millions except per share, conversion factor applied.
2020 August 31st | 2021 August 31st | 2022 August 31st | 2023 August 31st | 2024 August 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 8.59 | 8.05 | 6.06 | 6.78 | 0.75 |
| Operating Profit | -8.59 | -8.05 | -6.06 | -6.78 | -0.75 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -8.54 | -7.73 | -6.05 | -6.78 | -0.503 |
| Net Income After Taxes | -8.54 | -7.73 | -6.05 | -6.78 | -0.503 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -8.54 | -7.73 | -6.05 | -6.78 | -0.503 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -8.54 | -7.73 | -6.05 | -6.78 | -0.503 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -2.45 | -1.24 | -0.866 | -0.346 | -0.108 |